Return to search

Oxford Promotes Fambrough

Oxford Bioscience Partners has promoted Douglas Fambrough to the position of general partner. He joined the firm in January 2000 as an associate, after having been a genomic scientist with what is now known as the Broad Institute. He led Oxford's deal for Sirna Therapeutics (acquired by Merck for $1.1b), and also was involved with Solexa (sold to Illumina for $550m).